PTC Therapeutics, Inc. Current State and Local Tax Expense (Benefit)
PTC Therapeutics, Inc. (PTCT) reported Current State and Local Tax Expense (Benefit) of $4.40 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentStateAndLocalTaxExpenseBenefit · last filed 2026-02-19
- PTC Therapeutics, Inc. current state and local tax expense (benefit) for the quarter ending 2020-12-31 was $2.88M.
- PTC Therapeutics, Inc. current state and local tax expense (benefit) for the quarter ending 2020-09-30 was $22.10M.
- PTC Therapeutics, Inc. current state and local tax expense (benefit) for fiscal 2025 was $4.40M, a 77.36% decline from fiscal 2024.
- PTC Therapeutics, Inc. current state and local tax expense (benefit) for fiscal 2024 was $19.42M.
- PTC Therapeutics, Inc. current state and local tax expense (benefit) for fiscal 2023 was -$27.23M, a 744.55% decline from fiscal 2022.
- PTC Therapeutics, Inc. current state and local tax expense (benefit) for fiscal 2022 was $4.22M, a 9.89% increase from fiscal 2021.
| Period end | Current State and Local Tax Expense (Benefit) 3 month | Current State and Local Tax Expense (Benefit) 6 month | Current State and Local Tax Expense (Benefit) 9 month | Current State and Local Tax Expense (Benefit) 12 month | Current State and Local Tax Expense (Benefit) 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $4.40M 10-K · filed 2026-02-19 | ||||
| 2024-12-31 | $19.42M 10-K · filed 2026-02-19 | ||||
| 2023-12-31 | -$27.23M 10-K · filed 2026-02-19 | ||||
| 2022-12-31 | $4.22M 10-K · filed 2025-02-27 | ||||
| 2021-12-31 | $3.84M 10-K · filed 2024-02-29 | ||||
| 2020-12-31 | $2.88M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $24.98M derived: sum of 2 quarters · filed 2023-02-21 | $24.98M 10-K · filed 2023-02-21 | ||
| 2020-09-30 | $22.10M 10-Q · filed 2020-10-29 | $22.10M 10-Q · filed 2020-10-29 | |||
| 2019-12-31 | $61.00K 10-K · filed 2022-02-22 | ||||
| 2018-12-31 | $38.00K 10-K · filed 2021-02-25 | ||||
| 2017-12-31 | $6.00K 10-K · filed 2020-03-02 | ||||
| 2016-12-31 | $2.00K 10-K · filed 2019-03-01 | ||||
| 2015-12-31 | $2.00K 10-K · filed 2018-03-06 | -$2.00K 10-K · filed 2016-02-29 | |||
| 2014-12-31 | -$4.89M 10-K · filed 2017-03-16 | ||||
| 2013-12-31 | $2.00K 10-K · filed 2015-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |